Recombinant Chinese Hamster Ovary Cell Market - Forecast(2024 - 2030)
Recombinant Chinese Hamster Ovary Cell Market Overview
Recombinant Chinese Hamster Ovary Cell Market size is estimated to reach $321.3 million by 2027, growing at a CAGR of 5.2% during the forecast period 2022-2027. A CHO can be demarcated as an epithelial cell line that is derived from the ovary of a native Chinese rodent, “Chinese hamster.” CHO plays a significant role in various medical and biological research activities. CHO cells are prone to cell transfection, genetic modification, clone selection, and recombinant protein expressions. These cells exhibit a lower number of chromosomes; therefore, they are proficient in radiation cytogenetics and tissue culture. Moreover, CHO cells help in investigating genetic mutations as they do not express the epidermal growth receptor factor (EGFR). Owing to their ability to undergo post-translational modifications, CHO holds several pharmaceutical applications. The recombinant CHO cells market outlook is fairly enchanting owing to widescale usage in recombinant protein therapeutics. Across-the-board applications in research and study of genetics and humanized immunoglobulin G (IgG) biopharmaceuticals production are factors set to drive the growth of the Recombinant Chinese Hamster Ovary Cell Market for the period 2022-2027.
Report Coverage
The report: “Recombinant Chinese Hamster Ovary Cell Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Recombinant Chinese Hamster Ovary Cell Market.
Key Takeaways
- Geographically, the North America Recombinant Chinese Hamster Ovary Cell Market accounted for the highest revenue share in 2021. The growth is owing to state-of-the-art research facilities and top-flight professionals.
- Technological breakthroughs, heightening research spending in both developed and developing countries, and spiraling prevalence of infectious ailments are said to be preeminent drivers driving the growth of the Recombinant Chinese Hamster Ovary Cell Market. Exorbitant research activities, hampered operations because of the COVID, and the dearth of enough skilled professionals are said to reduce the market growth.
- Detailed analysis of the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Recombinant Chinese Hamster Ovary Cell Market report.
Recombinant Chinese Hamster Ovary Cell Market Share, By Geography (%) in 2021
For more details on this report - Request for Sample
Recombinant Chinese Hamster Ovary Cell Market Segment Analysis-By Applications
The Recombinant Chinese Hamster Ovary Cell Market based on the applications can be further segmented into biotherapeutic and API production, Genetic studies, Gene expression, Toxicity screening, and Others. The biotherapeutics and active pharmaceutical ingredients production segment held the largest share in 2021. The growth is owing to the growing prevalence of vaginal infections, cancer, Clostridium difficile infections, and other chronic illnesses. Biopharmaceutics is termed medicines that are manufactured with the help of biological means, and they play a significant role in treating the aforementioned health complications. Active pharmaceuticals are the base of every medicine produced anywhere in the world. Therefore, without their production, it won’t be possible for companies to manufacture medicinal drugs. As a result, considering the proliferating swell in acute and chronic maladies the same segment is estimated to be the fastest-growing segment with a CAGR of 6.6% over the forecast period 2022-2027.
Recombinant Chinese Hamster Ovary Cell Market Segment Analysis-By End-User
The Recombinant Chinese Hamster Ovary Cell Market based on end-user can be further segmented into CROs, Biopharmaceutical companies, Research laboratories or institutes, and Others. The biopharmaceutical companies segment held the largest share in 2021. The growth is owing to the rising demand for better and more effective therapeutics as several infectious diseases are roaming around the world. Therefore, biopharmaceutical companies have ramped up their efforts to develop novel therapeutics. Similarly, the biopharmaceutical segment is estimated to be the fastest-growing with a CAGR of 6.8% over the forecast period 2022-2027. This growth is owing to the rising means and expertise of companies to better execute their operations as they are undergoing several mergers and acquisition activities. In addition to that, CHO cells' significance in inspecting genetic mutations has provided several growth opportunities to the aforementioned market in the said segment.
Recombinant Chinese Hamster Ovary Cell Market Segment Analysis-By Geography
The Recombinant Chinese Hamster Ovary Cell Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 40% of the overall market in 2021. The growth in this segment is owing to the factors such as well-established healthcare infrastructure and economic affluence. The American healthcare infrastructure is deemed to be the best in the world. Moreover, the US is home to several world-renowned research facilities and academic institutions such as Harvard, Stanford, and MIT. Moreover, quality lifestyles and sound salary packages have helped developed countries like Canada and the US to attract top-notch talent from around the globe. However, Asia-Pacific is expected to be the fastest-growing segment over the forecast period 2022-2027. This growth is owing to bettering healthcare infrastructure as Asia is emerging as the new wealth center of the world. Governments of various developing nations such as India, China, and Indonesia are allocating comfortable packages to ameliorate existing infrastructure.
Recombinant Chinese Hamster Ovary Cell Market Drivers
Widescale usage in biotherapeutics production is anticipated to boost market demand.
The overall demand for biotherapeutics has witnessed an unprecedented surge in recent years as the world reeling under the weight of several infections and severe illnesses like cancer. Millions have lost their lives because of COVID-19. On another hand, cancer has become a headache, especially in developed countries like the US. In 2021, nearly 1.9 million cases and over 608,500 deaths were reported in the US. On another hand, with expanding acute health complications, the over usage of antibiotics has resulted in a high prevalence of clostridium difficile infection. According to toa report, around 200,000 people in the US develop this condition every year. Therefore, the high demand for CHO cells has heightened the growth of the recombinant Chinese hamster ovary cell market.
Augmenting research spending in developing countries is expected to boost market demand.
Refining healthcare infrastructure and growing economic prosperity have been prime stimuli for the recombinant Chinese hamster ovary cell market. As developing countries like China are achieving new export milestones despite the pandemic, the government has more means to spend on healthcare amelioration and research activities. With a 6.09 percent rise, China spent nearly $26.84 billion on research and development in 2021. Moreover, the Chinese government allocating staggering packages to ramp up the existing healthcare infrastructure.
Recombinant Chinese Hamster Ovary Cell Market Challenges
The dearth of skilled professionals, extortionate research activities, and hampered research operations are Anticipated to hamper the market growth.
The requirement of well-established and world-class laboratories is the biggest prerequisite for executing research activities effectively. However, setting up such facilities requires an innumerable flow of hard cash which the majority of the developing and underdeveloped countries can not afford. According to Edelweiss, there are around 1,216 NABL accredited labs, which is ~1% of total labs in India and works out to less than 1 lab per million. The top 4 players have the maximum number of NABL accredited labs. Though the number of accredited labs in India has been growing at 16% CAGR to 1,216 in 2020 from 576 in 2015, there is still a long way to go to reach the numbers of peer nations such as the UK, US, and Australia, which have more than 10 labs per million. Moreover, too often brilliant minds from underdeveloped worlds flee to developed nations in order to lead a quality lifestyle which eventually impacts poor countries adversely. On another hand, the shortage of top-flight and highly skilled professionals is another major factor that challenges the steady growth of the aforementioned market.
Recombinant Chinese Hamster Ovary Cell Industry Outlook:
Product
launches, mergers and acquisitions, joint ventures, and geographical expansions
are key strategies adopted by players in the aforementioned Market. Recombinant
Chinese Hamster Ovary Cell market top 10 companies include-
- WuXi
Biologics
- Celonic
Group
- Thermo
Fisher Scientific
- Selexis
SA
- Merck
- JSR
Life Sciences
- Cygnus
Technologies
- Trenzyme
GmbH
- ProBioGen
- LakePharma
Recent Developments
- On September 3, 2021, Curia (a New York, United States-based contract research, development, and manufacturing organization (CDMO) known for its drug development services) announced that it has successfully acquired California, United States-based biologics CRDMO “LakePharma.” The acquisition has strengthened the fill-finish and drug substance manufacturing expertise of Curia.
- On May 7, 2021, China-based contract research, development, and manufacturing organization WuXi Biologics announced the 3 successful acquisitions. the company publicized the acquisition of Jiangsu-based CMAD Biopharma group and manufacturing facility from US-based pharmaceutical company Pfizer and German life sciences company Bayer.
- On April 15, 2021, Massachusetts, United States-based firm Thermo Fisher Scientific (a company that supplies various scientific instruments and reagents, and consumables) announced the successful acquisition of PPD (a North Carolina, United States-based CRO committed to drug development). Thermo Fisher made an overwhelming payment of $17.4 billion in order to complete the acquisition.
Relevant Links:
LIST OF TABLES
1.Global GLOBAL RECOMBINANT CHINESE HAMSTER OVARY CELL HEPATITIS B VACCINE MARKET, BY END USER Market 2023-2030 ($M)1.1 PEDIATRIC HEPATITIS B VACCINE Market 2023-2030 ($M) - Global Industry Research
1.2 ADULT HEPATITIS B VACCINE Market 2023-2030 ($M) - Global Industry Research
2.Global GLOBAL RECOMBINANT CHINESE HAMSTER OVARY CELL HEPATITIS B VACCINE MARKET, BY END USER Market 2023-2030 (Volume/Units)
2.1 PEDIATRIC HEPATITIS B VACCINE Market 2023-2030 (Volume/Units) - Global Industry Research
2.2 ADULT HEPATITIS B VACCINE Market 2023-2030 (Volume/Units) - Global Industry Research
3.North America GLOBAL RECOMBINANT CHINESE HAMSTER OVARY CELL HEPATITIS B VACCINE MARKET, BY END USER Market 2023-2030 ($M)
3.1 PEDIATRIC HEPATITIS B VACCINE Market 2023-2030 ($M) - Regional Industry Research
3.2 ADULT HEPATITIS B VACCINE Market 2023-2030 ($M) - Regional Industry Research
4.South America GLOBAL RECOMBINANT CHINESE HAMSTER OVARY CELL HEPATITIS B VACCINE MARKET, BY END USER Market 2023-2030 ($M)
4.1 PEDIATRIC HEPATITIS B VACCINE Market 2023-2030 ($M) - Regional Industry Research
4.2 ADULT HEPATITIS B VACCINE Market 2023-2030 ($M) - Regional Industry Research
5.Europe GLOBAL RECOMBINANT CHINESE HAMSTER OVARY CELL HEPATITIS B VACCINE MARKET, BY END USER Market 2023-2030 ($M)
5.1 PEDIATRIC HEPATITIS B VACCINE Market 2023-2030 ($M) - Regional Industry Research
5.2 ADULT HEPATITIS B VACCINE Market 2023-2030 ($M) - Regional Industry Research
6.APAC GLOBAL RECOMBINANT CHINESE HAMSTER OVARY CELL HEPATITIS B VACCINE MARKET, BY END USER Market 2023-2030 ($M)
6.1 PEDIATRIC HEPATITIS B VACCINE Market 2023-2030 ($M) - Regional Industry Research
6.2 ADULT HEPATITIS B VACCINE Market 2023-2030 ($M) - Regional Industry Research
7.MENA GLOBAL RECOMBINANT CHINESE HAMSTER OVARY CELL HEPATITIS B VACCINE MARKET, BY END USER Market 2023-2030 ($M)
7.1 PEDIATRIC HEPATITIS B VACCINE Market 2023-2030 ($M) - Regional Industry Research
7.2 ADULT HEPATITIS B VACCINE Market 2023-2030 ($M) - Regional Industry Research
LIST OF FIGURES
1.US Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)2.Canada Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
3.Mexico Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
4.Brazil Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
5.Argentina Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
6.Peru Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
7.Colombia Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
8.Chile Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
9.Rest of South America Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
10.UK Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
11.Germany Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
12.France Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
13.Italy Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
14.Spain Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
15.Rest of Europe Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
16.China Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
17.India Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
18.Japan Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
19.South Korea Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
20.South Africa Recombinant Chinese Hamster Ovary Cell Market Revenue, 2023-2030 ($M)
21.North America Recombinant Chinese Hamster Ovary Cell By Application
22.South America Recombinant Chinese Hamster Ovary Cell By Application
23.Europe Recombinant Chinese Hamster Ovary Cell By Application
24.APAC Recombinant Chinese Hamster Ovary Cell By Application
25.MENA Recombinant Chinese Hamster Ovary Cell By Application
26.MERCK CO., INC., Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.GLAXOSMITHKLINE PLC, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.SANOFI PASTEUR, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.EMERGENT BIOSOLUTIONS, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.SERUM INSTITUTE OF INDIA, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.JOHNSON JOHNSON, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.CSL LIMITED, Sales /Revenue, 2015-2018 ($Mn/$Bn)